ERBB2 and gastric cancer: A high-throughput 1015 Exiqon miRCURY LNATM microRNA inhibitor library screen was performed in trastuzumab-treated HER2-positive NCI-N87 and HER2-negative FLO-1 oesophago-gastric cancer cell lines.